Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma
NCT02040766 · View on ClinicalTrials.gov ↗
Study Summary
This randomized, double-blind, double-dummy, placebo-controlled, parallel-group, 12-week study will evaluate the efficacy and safety of beclomethasone dipropionate (80 or 160 mcg/day) administered via breath-actuated inhaler (BAI) and metered-dose inhaler (MDI) in pediatric patients 4 through 11 years of age with persistent asthma, compared with placebo. Patients took 1 inhalation (with assistance from parents/guardians/caregivers, as needed) from each of 2 devices (BAI device followed by MDI device in that order) twice daily as per the double-dummy study design: 1 BAI treatment or placebo device and 1 MDI treatment or placebo device for a total of 2 inhalations each time.
Conditions Studied
Interventions
- DRUG Placebo MDI
- DRUG Beclomethasone dipropionate BAI
- DRUG Placebo BAI
- DRUG albuterol/salbutamol 90 mcg
- DRUG Beclomethasone dipropionate MDI
Study Locations (20)
California
- Teva Investigational Site 10903 — Costa Mesa
- Teva Investigational Site 10911 — Downey
- Teva Investigational Site 10901 — Huntington Beach
- Teva Investigational Site 12297 — Huntington Beach
- Teva Investigational Site 10880 — Mission Viejo
- Teva Investigational Site 10895 — Orange
- Teva Investigational Site 10924 — Paramount
- Teva Investigational Site 10910 — Rolling Hills Estates
- Teva Investigational Site 12343 — Roseville
- Teva Investigational Site 12298 — San Diego
- Teva Investigational Site 12300 — San Diego
- Teva Investigational Site 12295 — San Jose
- Teva Investigational Site 12312 — West Covina
Alabama
- Teva Investigational Site 12346 — Hoover
- Teva Investigational Site 12294 — Montgomery
Colorado
- Teva Investigational Site 10937 — Centennial
- Teva Investigational Site 10899 — Colorado Springs
Arizona
- Teva Investigational Site 10925 — Phoenix
Arkansas
- Teva Investigational Site 12349 — Little Rock
Florida
- Teva Investigational Site 10894 — Aventura
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 628 participants |
| Start Date | 2013-12 |
| Est. Completion | 2016-03 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02040766
The ClinicalTrials.gov registry entry for NCT02040766 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 628 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 103 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 5 interventions — of which Placebo MDI is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT02040766 reports 20 study locations spanning 6 distinct geographic areas — top geographies include California, Alabama, Colorado. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT02040766 about?
NCT02040766 is a clinical study titled "A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma". This randomized, double-blind, double-dummy, placebo-controlled, parallel-group, 12-week study will evaluate the efficacy and safety of beclomethasone dipropionate (80 or 160 mcg/day) administered via breath-actuated inhaler (BAI) and metered-dose inhaler (MDI) in pediatric patients 4 through 11 yea...
What is the current status of trial NCT02040766?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 628 participants. The study started on 2013-12. Estimated completion is 2016-03.
What conditions does trial NCT02040766 study?
This clinical trial studies the following conditions: Asthma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT02040766?
The interventions under investigation include: Placebo MDI (DRUG), Beclomethasone dipropionate BAI (DRUG), Placebo BAI (DRUG), albuterol/salbutamol 90 mcg (DRUG), Beclomethasone dipropionate MDI (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT02040766?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 103 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT02040766 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.